Cargando…

Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(®) protein MP0250: a preclinical study

The investigational drug MP0250 is a multi-specific DARPin(®) molecule that simultaneously binds and neutralizes VEGF and HGF with high specificity and affinity. Here we studied the antiangiogenic effects of the MP0250 in multiple myeloma (MM). In endothelial cells (EC) isolated from bone marrow (BM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, Luigia, De Veirman, Kim, Giannico, Donato, Saltarella, Ilaria, Desantis, Vanessa, Frassanito, Maria Antonia, Solimando, Antonio Giovanni, Ribatti, Domenico, Prete, Marcella, Harstrick, Andreas, Fiedler, Ulrike, De Raeve, Hendrik, Racanelli, Vito, Vanderkerken, Karin, Vacca, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862584/ https://www.ncbi.nlm.nih.gov/pubmed/29568363 http://dx.doi.org/10.18632/oncotarget.24351

Ejemplares similares

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
por: Baird, Richard D., et al.
Publicado: (2021)

MP0250, a VEGF and HGF neutralizing DARPin(®) molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models
por: Fiedler, Ulrike, et al.
Publicado: (2017)

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
por: Lamanuzzi, Aurelia, et al.
Publicado: (2018)

MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
por: Desantis, Vanessa, et al.
Publicado: (2020)

Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma
por: Desantis, V., et al.
Publicado: (2018)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
por: Solimando, Antonio Giovanni, et al.
Publicado: (2019)

Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression
por: Saltarella, Ilaria, et al.
Publicado: (2021)

Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients
por: Lamanuzzi, Aurelia, et al.
Publicado: (2016)

MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease
por: Desantis, Vanessa, et al.
Publicado: (2021)

Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2014)

The Landscape of lncRNAs in Multiple Myeloma: Implications in the “Hallmarks of Cancer”, Clinical Perspectives and Therapeutic Opportunities
por: Saltarella, Ilaria, et al.
Publicado: (2022)

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
por: Melaccio, Assunta, et al.
Publicado: (2022)

Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?()
por: Saltarella, Ilaria, et al.
Publicado: (2018)

HB-EGF–EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma
por: Rao, Luigia, et al.
Publicado: (2020)

Mast Cells and Interleukins
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, ex vivo and in vitro Analysis
por: Cicco, Sebastiano, et al.
Publicado: (2022)

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications
por: Stahl, Andreas, et al.
Publicado: (2012)

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
por: Ria, Roberto, et al.
Publicado: (2020)

DARPins: Promising Scaffolds for Theranostics
por: Shilova, O. N., et al.
Publicado: (2019)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer
por: Ribatti, Domenico, et al.
Publicado: (2021)

EHMTI-0250. General practitioners’ experiences with brief intervention for medication-overuse headache: a qualitative study
por: Kristoffersen, ES, et al.
Publicado: (2014)

Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications
por: Lamanuzzi, Aurelia, et al.
Publicado: (2023)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2020)

Beyond Antibodies: The DARPin(®) Drug Platform
por: Stumpp, Michael T., et al.
Publicado: (2020)

On the prevention of kidney uptake of radiolabeled DARPins
por: Altai, Mohamed, et al.
Publicado: (2020)

LmxM.22.0250-Encoded Dual Specificity Protein/Lipid Phosphatase Impairs Leishmania mexicana Virulence In Vitro
por: Kraeva, Natalya, et al.
Publicado: (2019)

Bivalent EGFR-Targeting DARPin-MMAE Conjugates
por: Karsten, Lennard, et al.
Publicado: (2022)

Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives
por: Saltarella, Ilaria, et al.
Publicado: (2022)

Anti-Angiogenic Activity of Drugs in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2023)

Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study
por: Cicco, Sebastiano, et al.
Publicado: (2020)

Antibiotics or No Antibiotics, That Is the Question: An Update on Efficient and Effective Use of Antibiotics in Dental Practice
por: Buonavoglia, Alessio, et al.
Publicado: (2021)

Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
por: Solimando, Antonio Giovanni, et al.
Publicado: (2020)

Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration
por: Callanan, David, et al.
Publicado: (2018)

Programmable DARPin-based receptors for the detection of thrombotic markers
por: Strittmatter, Tobias, et al.
Publicado: (2022)

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus
por: Barć, Piotr, et al.
Publicado: (2020)

MBP-binding DARPins facilitate the crystallization of an MBP fusion protein
por: Gumpena, Rajesh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nv1ppnki045nfv083soll7ph6j